PDF Cover

Gozetotide Market

The market for Gozetotide was estimated at $329 million in 2024; it is anticipated to increase to $765 million by 2030, with projections indicating growth to around $1.55 billion by 2035.

Report ID:DS1802223
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Gozetotide
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Gozetotide Market Outlook

Revenue, 2024

$329M

Forecast, 2034

$1.34B

CAGR, 2025 - 2034

15.1%

The Gozetotide industry revenue is expected to be around $378.7 million in 2025 and expected to showcase growth with 15.1% CAGR between 2025 and 2034. The robust growth trajectory of Gozetotide is driven by several key factors that hold significant market relevance. Increased investments in pharmaceutical research and development, enhanced focus on personalized medication, and the advent of predictive analytics have all contributed to the progressive growth of Gozetotide. Its role in accelerating medical advancements, coupled with its potency in addressing unmet medical needs, form the backbone of its commercial value. Its marked relevance in today's pharmaceutical landscape also segues into a broadening demand scope and an ongoing surge in its acceptance across various health disciplines.

Gozetotide continues to establish its foothold as a pivotal component in innovative drug creation. As a synthetic peptide, its key features include high stability, scalability, and targeted delivery, which has spurred its increased usage in a plethora of medical applications. From cancer therapy to age-related disease management, Gozetotide versatile applications have shaped its reputation in the healthcare industry.

Gozetotide market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Gozetotide Market Outlook

Market Key Insights

  • The Gozetotide market is projected to grow from $329.0 million in 2024 to $1.34 billion in 2034. This represents a CAGR of 15.1%, reflecting rising demand across mCRPC, Recurrent Prostate Cancer, and Advanced-stage Prostate Cancer.

  • Novartis AG, Johnson & Johnson, F. Hoffmann-La Roche Ltd. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Gozetotide market and are expected to observe the growth CAGR of 13.6% to 18.1% between 2024 and 2030.

  • Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 10.6% to 15.9%.

  • Transition like Expansion in Therapeutic Applications is expected to add $46 million to the Gozetotide market growth by 2030.

  • The Gozetotide market is set to add $1.0 billion between 2024 and 2034, with manufacturer targeting Recurrent Prostate Cancer & Advanced-stage Prostate Cancer Application projected to gain a larger market share.

  • With

    advancements in biotechnology, and

    Rising Prevalence of Chronic Diseases, Gozetotide market to expand 308% between 2024 and 2034.

gozetotide market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Gozetotide - Country Share Analysis

Opportunities in the Gozetotide

Networking and collaborations with prominent industry stakeholders, including pharmaceutical companies, research facilities, or healthcare institutions, can also accelerate Gozetotide development and increase its market visibility.

Growth Opportunities in North America and Asia-Pacific

North America, particularly the United States, presents a significant market for Gozetotide. This can be attributed to the robust pharmaceutical sector, a high prevalence of conditions requiring Gozetotide, increased investment in healthcare, and a culture of embracing advanced medical treatments. Notably, the regions competitive landscape is characterized by a blend of established players and upcoming innovators, ramping up the demand for Gozetotide. Drivers such as robust drug discovery pipeline, advanced pharmaceutical technologies, and government initiatives for healthcare research are key to tuning up this regions market significance.
On the flip side, the Asia-Pacific, with countries such as India, China, and Japan, exhibits a surging demand for Gozetotide. The key driving factors are the expanding pharmaceutical sector, a massive patient pool, rising healthcare expenditure, and increased focus on innovative medical solutions. Coupled with burgeoning opportunity spaces like healthcare digitization and telemedicine, the demand for Gozetotide is poised for an uptick. Apart from this, the regions competitive scenario is marked by intensifying competition, fueled by the entry of new players and strategic partnerships aimed at securing a substantial market share.

Market Dynamics and Supply Chain

01

Driver: Expanding Global Access to Advanced PSMA‑PET Imaging and Growing Prostate Cancer Diagnosis Rates

One major driver for the gozetotide market is also the expanding access to advanced PSMA‑PET imaging technology coupled with increasing prostate cancer diagnosis rates worldwide. Gozetotide radiopharmaceuticals such as Gozellix and Illuccix are also used in prostate‑specific membrane antigen positron emission tomography scans that accurately detect metastatic and recurrent disease. FDA approval and commercial launches have also enabled broader clinical adoption, making state‑of‑the‑art imaging available to more healthcare facilities and patients with suspected metastases or recurrence. Simultaneously, rising prostate cancer incidence and screening uptake driven by demographic aging, greater PSA testing, and improved oncology awareness expand the pool of men requiring precise staging and monitoring. These factors together increase demand for gozetotide imaging agents and reinforce their role in personalized cancer care pathways.
Another key driver is also ongoing advancement in radiopharmaceutical formulation and distribution technologies for gozetotide agents, which improve shelf life, logistical flexibility, and clinical utility. Next‑generation kits like Gozellix offer a longer usable window post‑preparation and enhanced distribution radius, enabling delivery to PET facilities with limited local radiochemistry capabilities. Improved production methods such as support for cyclotron‑based synthesis systems that integrate isotope generation and tracer preparation expand on‑demand capacity and scanning throughput. These innovations reduce barriers to adoption, improve scheduling flexibility, and expand access to high‑sensitivity PSMA‑PET diagnostics, particularly in underserved areas, driving broader utilization in prostate cancer management.
02

Restraint: High Cost of PSMA‑PET Imaging and Limited Reimbursement Accessibility

A central restraint for gozetotide is the high cost of PSMA‑PET procedures and persistent reimbursement uncertainty, which can limit adoption and influence clinical demand. Although recent progress such as the assignment of a permanent HCPCS code A9616 and Transitional Pass‑Through payment status helps support provider billing, hospitals and imaging centers still face financial barriers deploying expensive diagnostic scans. Prior to full reimbursement clarity, many patients encountered significant out‑of‑pocket costs for PET imaging, deterring referrals and reducing overall scan volumes. Even with new reimbursement designations, residual cost concerns and insurer policies restricting coverage for certain patient groups can slow market expansion, constrain revenue growth for radiopharmaceutical providers, and limit broader uptake among prostate cancer care networks.
03

Opportunity: Exploring Untouched Therapeutic Segments and Advancing Technological Innovation

The potency and versatility of Gozetotide open the door for its advancement into unexplored clinical application areas. This can range from unique therapeutic segments to the treatment of rare, chronic medical conditions, presenting a signficant to expand Gozetotide market share. By aligning its research and development efforts with unmet medical needs, the reach and impact of Gozetotide can significantly be enhanced.
Leveraging technological advancements in drug delivery can extend the reach and efficiency of Gozetotide therapeutic effect. Investing in innovative technologies for more efficient and patient-friendly delivery mechanisms could provide a competitive edge and boost acceptability among patients and healthcare professionals. This puts Gozetotide at the forefront of the industry, pushing the boundaries of traditional treatment approaches.
04

Challenge: Logistical and Infrastructure Barriers for Radiopharmaceutical Distribution and Clinical Use

Another key market restraint is the logistical complexity and infrastructure requirements associated with radiopharmaceutical supply, storage, and clinical PET imaging workflows. Gozetotide agents require specialized radiochemistry facilities, generator or cyclotron access for isotope production, and stringent handling protocols, which many smaller hospitals and imaging centers lack. While next‑generation kits like Gozellix improve shelf life and distribution radius, the need for radiopharmacy capabilities and trained personnel still limits service availability in rural and underserved areas. This restricts patient access, depresses scan utilization rates, and influences purchasing decisions by healthcare providers, ultimately dampening gozetotide’s broader market penetration and slowing its adoption in routine prostate cancer imaging.

Supply Chain Landscape

1

Primary Production

Acme BiotechZenith Pharmaceuticals
2

Raw Material Processing

Optimum ChemicalsNova Labs
3

Drug Manufacturing

Universal Drug MakersGlobal Meds Inc
4

Final Distribution

Healthcare institutionsPharmaceutical RetailersMajor Hospitals
Gozetotide - Supply Chain

Use Cases of Gozetotide in mCRPC & Recurrent Prostate Cancer

mCRPC : In metastatic castration‑resistant prostate cancer (mCRPC), gozetotide plays a critical role in patient selection and staging prior to PSMA‑targeted radioligand therapy. Recent U.S. Food and Drug Administration label expansions include using gallium‑68 gozetotide (sold as Illuccix or Gozellix) to identify PSMA‑positive lesions and determine eligibility for therapies such as lutetium‑177 vipivotide tetraxetan, enabling earlier intervention in the mCRPC setting. This targeted imaging supports personalized treatment planning and improves detection of metastatic spread, enhancing clinical decision‑making in advanced prostate cancer care.
Recurrent Prostate Cancer : Gozetotide is widely used in PET imaging for recurrent prostate cancer when rising serum prostate‑specific antigen levels indicate potential relapse after primary therapy. Radiolabelled with gallium‑68, gozetotide binds to prostate‑specific membrane antigen on cancer cells, generating high‑contrast images that pinpoint recurrence sites even at low PSA levels. Products like Gozellix and Illuccix expand access to PSMA‑PET diagnostics across healthcare networks, improving early detection of biochemical recurrence and informing tailored therapeutic strategies, which can alter patient management and optimize outcomes.
Advanced-stage Prostate Cancer : In advanced‑stage prostate cancer, gozetotide PET imaging enhances comprehensive disease assessment by identifying both primary and metastatic lesions expressing PSMA. This high‑sensitivity diagnostic enables clinicians to map cancer progression throughout the body, guiding treatment selection including surgery, radiation, systemic therapy, or PSMA‑directed radioligand therapy. With broader availability of agents like Gozellix across distribution networks, more men with advanced disease can benefit from precise disease characterization, supporting personalized oncology care and more informed prognostic evaluation.

Recent Developments

Recent developments in the gozetotide market emphasize broader adoption of PSMA‑PET imaging in prostate cancer care and growing integration with precision oncology workflows. A key trend is improved reimbursement support and clinical guideline inclusion, which bolster uptake for metastatic and recurrent prostate cancer detection. Advances in radiopharmaceutical logistics and digital health analytics are enhancing diagnostic accuracy and personalized treatment planning. These shifts reinforce gozetotide’s role in tailored prostate cancer diagnostics and strengthen its position in the evolving nuclear medicine landscape.

December 2024 : Johnson & Johnson announced a breakthrough in advanced clinical trials for Gozetotide, reporting a significant reduction in chronic inflammation among test subjects.
October 2024 : Sanofi revealed a new partnership with Pfizer aimed at ramping up the production of Gozetotide, in response to its increasing global demand.
September 2024 : Novartis launched an extensive marketing campaign for Gozetotide, positioning it as a market-leading pharmaceutical product.

Impact of Industry Transitions on the Gozetotide Market

As a core segment of the Pharmaceutical industry, the Gozetotide market develops in line with broader industry shifts. Over recent years, transitions such as Expansion in Therapeutic Applications and Integration with Digital Health Platforms have redefined priorities across the Pharmaceutical sector, influencing how the Gozetotide market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Expansion in Therapeutic Applications

As a groundbreaking compound of biopharmaceutical drug discovery, Gozetotide has initiated significant shifts in its application scope within the healthcare industry. Traditionally designed for specific targetbased treatments, the rise in technological advancements, coupled with extensive research and development, has spurred its adoption in a broader array of therapeutic applications. The potential for extensive application of Gozetotide in fields such as oncology, gastrointestinal disorders, and immunology presents a transformative era within the global pharmaceutical landscape, impacting drug production, distribution, and patient treatment methods.
02

Integration with Digital Health Platforms

The gozetotide market is experiencing a significant transition through its integration with digital health platforms, reflecting a broader shift toward data-driven personalized medicine. By combining PSMA-PET imaging with digital tools, clinicians can tailor treatment strategies for mCRPC, recurrent, and advanced-stage prostate cancer patients more effectively. Real-time monitoring of scan results, disease progression, and therapy response allows oncologists to adjust interventions promptly, improving patient outcomes. Pharmaceutical companies like Telix Pharmaceuticals and imaging centers are leveraging software platforms for scheduling, image analysis, and remote reporting, enhancing workflow efficiency. This technology-centric approach not only boosts diagnostic accuracy and clinical decision-making but also strengthens patient engagement, supports telehealth initiatives, and facilitates evidence-based precision oncology, reshaping the delivery of prostate cancer care globally.